Pacira Biosciences received FDA approval for an enhanced manufacturing process for Exparel, a postsurgical injectable anesthetic.
The manufacturing process is housed at a facility in England through a partnership with Thermo Fisher Scientific Pharma Services, according to an Aug. 2 news release. Products made at the facility are expected to sell later in the year.
"This FDA approval underscores the quality assurance of our enhanced manufacturing process, which is essential as we scale the production of Exparel," CEO and Chair Dave Stack said. "Launching this new manufacturing site marks an important milestone for Pacira that will allow us to double our capacity to meet the growing demand for Exparel, while simultaneously improving our gross margins and extending our market exclusivity into 2041."